Rekvina Laboratories Ltd
Rekvina Laboratories Ltd (VINRKLB) last traded at ₹46, a market capitalisation of ₹51.1 crore. Over the past 52 weeks the stock has ranged between ₹6.75 and ₹46.6. Rekvina Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹0.67 crore and net profit of ₹-0.12 crore. Figures are as of 25 Aug 2026 and are not real time.
Rekvina Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Rekvina Laboratories Ltd quarterly results
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0.2 | 0.35 | 0.72 | 0.67 |
| Expenses | 0.07 | 0.02 | 0.04 | 0.04 | 0.23 | 0.47 | 0.78 | 0.79 |
| Operating profit | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| OPM % | — | — | — | — | -15.00% | -34.29% | -8.33% | -17.91% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.07 | -0.02 | -0.04 | -0.04 | -0.03 | -0.12 | -0.06 | -0.12 |
| EPS (₹) | -0.06 | -0.02 | -0.03 | -0.03 | -0.02 | -0.10 | -0.05 | -0.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Rekvina Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 0 | -0.04 | 0 | 0 | 0 | 1.27 | 1.94 |
| Operating profit | -0.06 | -0.08 | 0 | -0.02 | -0.14 | -0.25 | -0.33 |
| OPM % | — | — | — | — | — | -19.69% | -17.01% |
| Net profit | -0.06 | -0.08 | 0 | -0.02 | -0.14 | -0.25 | -0.33 |
| EPS (₹) | -0.05 | -0.07 | 0.00 | -0.02 | -0.12 | -0.21 | -0.27 |
TTM is the trailing twelve months to the most recent quarter.
Rekvina Laboratories Ltd growth and returns
- 10 Years
- 36%
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -94%
- 10 Years
- 24%
- 5 Years
- 63%
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Rekvina Laboratories Ltd shareholding pattern
Promoters held 77.00% at Aug 2026, up from 41.30% at Sep 2025.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 77.00% |
| Public | 58.70% | 58.70% | 58.71% | 58.72% | 58.72% | 58.72% | 58.70% | 23.00% |
| No. of shareholders | 2,430 | 2,427 | 2,442 | 2,427 | 504 | 2,475 | 2,465 | 2,457 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Rekvina Laboratories Ltd corporate filings
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Surbhit Mukesh Shah & OthersInsider Trading / SASThigh impact
Cruxal's analysis: Rekvina Laboratories Limited has undergone a significant change in shareholding…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhruvalkumar PatelInsider Trading / SASThigh impact
Cruxal's analysis: Dhruvalkumar Patel has acquired 11,12,562 equity shares of Rekvina Laboratories Limited…
Read the full analysis - Clarification on Price MovementCompany Updatelow impact
Cruxal's analysis: Rekvina Laboratories Ltd has issued a formal clarification regarding the recent movement…
Read the full analysis - OUTCOME OF BOARD MEETINGBoard Meetingmedium impact
Cruxal's analysis: Rekvina Laboratories Limited reported a net loss of 12.05 lakh for the quarter ended 30…
Read the full analysis - Allotment of Equity Shares on Preferential basisCompany Updatehigh impact
Cruxal's analysis: Rekvina Laboratories Limited has completed the acquisition of 100% equity in Radiant…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Rekvina Laboratories Ltd
Cruxal reads every Rekvina Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.